The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms

Figures & data

Table 1. Belief barriers and non-adherent (BMQ) in adherent and non-adherent patients (MASRI).

Level of adherence	4 weeks (n = 447)	8 weeks (n = 442)	12 weeks (n = 439)
Belief barriersMASRI <80%	51 (83.6%)61	89 (86.4%)103	148 (91.9%)161
Belief barriersMASRI ≥80%	26 (6.7%)**386	33 (9.7%)**339	31 (11.1%)**278
MASRI <80%BMQ <80%	61(94.3%)**63	103 (94.6%)**116	161 (98.8%)*163

MASRI: Medication adherence self-report inventory; BMQ: Brief Medication Questionnaire; BP: belief barrier Significance of differences *p ≤ 0.05; **p ≤ 0.01 (comparison between patients with <80% and ≥80% MASRI).

Figure 1. Changes in the percentage of patients LUTS who were identified of MASRY and BMQ as treatment adherence. LUTS: lower urinary tract symptoms, MASRI: questionnaire The Medication Adherence Self-Report Inventory, BMQ: Brief Medication Questionnaire.

Figure 2. ROC – curve of the MASRI as compared to the BMQ at 4, 8 and 12weeks (n = 629). AUC: area under curve, MASRI: Medication Adherence Self-Report Inventory, BMQ: Brief Medication Questionnaire.

Table 2. Significance of different cut points on the MASRI at 4, 8 and weeks study adherence of AM (n = 452).

	MASRI cut-off	Sensitivity	Specificity	Positive likelihood ratio
	≥80%	0.87 (0.12)	0.81 (0.11)	7.67 (4.35)
4 weeks	≥90%	0.87 (0.9)	0.90 (0.11)	9.11 (2.48)
n = 447	≥95%	0.91 (0.11)	0.94 (0.18)	13.6 (7.03)
	≥80%	0.88 (0.14)	0.85 (0.9)	6.39 (5.31)
8 weeks	≥90%	0.89 (0.11)	0.95 (0.13)	11.56 (4.58)
N = 442	≥95%	0.92 (0.15)	0.94 (0.11)	17.50 (7.72)
	≥80%	0.91 (0.12)	0.81 (0.17)	8.29 (5.46)
12 weeks	≥90%	0.90 (0.13)	0.91 (0.8)	15.7 (7.78)
N = 439	≥95%	0.92 (0.18)	0.94 (0.12)	18.8 (5.27)

MASRI: Medication adherence self-report inventory; CI: confidence interval.